Close Menu

NEW YORK (GenomeWeb) – Myriad Genetics is gearing up for a major commercialization push for BRACAnalysis CDx after gaining regulatory approval in the metastatic breast cancer setting and is working to expand reimbursement for the Vectra DA and GeneSight tests.

The company provided an update on its effort to grow adoption of its products during a call to discuss second quarter financial results of its fiscal year 2018. During that period, molecular diagnostics revenues declined 3 percent to $179.2 million, from $183.9 million a year ago.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.